Retrospective Review of Esophageal Cancer at MSKCC
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 4,000
- 试验地点
- 1
- 主要终点
- . Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery)
研究概览
简要总结
Residual tumor at the proximal or distal margin after esophagectomy is a known prognostic factor for poor survival outcomes in patients with esophageal cancer; however, the significance of the circumferential resection margin (CRM) remains controversial. In this study, the investigators sought to evaluate the prognostic significance of the CRM in patients with esophageal cancer undergoing resection.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy
- •Pathologic staged T3 tumors (pT3)
排除标准
- •Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)
- •Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,
- •Patients undergoing salvage esophagectomy
- •Evidence of distant metastatic disease
- •Patients with a positive proximal or distal margin
研究组 & 干预措施
Circumferential resection margin (CRM)
Participants will have a diagnosis of esophageal carcinoma and residual tumor >1 mm from the CRM
干预措施: Esophagectomy (Procedure)
Circumferential resection margin (CRM)-close
Participants will have a diagnosis of esophageal carcinoma and residual tumor >0-1 mm from the CRM
干预措施: Esophagectomy (Procedure)
Circumferential resection margin (CRM)+
Participants will have a diagnosis of esophageal carcinoma and residual tumor at the surgical CRM
干预措施: Esophagectomy (Procedure)
结局指标
主要结局
. Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery)
时间窗: Up to 2 years
Preoperative variables associated with overall survival and progression-free survival (measured from date of surgery) and the association between patient characteristics, neoadjuvant therapy, and postoperative morbidity.
次要结局
- Survival outcomes stratified by use of adjuvant therapy (i.e., adjuvant therapy or no adjuvant therapy).(Up to 2 years)
- Overall survival and progression-free survival (measured from date of surgery)(Up to 2 years)
- Postoperative outcomes stratified by the time between neoadjuvant therapy and surgery (i.e., delayed or immediate).(Up to 2 years)
- Survival outcomes stratified by treatment modality (i.e., definitive chemoradiation therapy or trimodality treatment).(Up to 2 years)